Diffusion Pharmaceuticals Inc., a clinical-stage biotechnology company, develops therapeutics for the treatment of cancer. Its lead product candidate is transcrocetinate sodium, which has initiated Phase 3 trials for the treatment of glioblastoma multiforme (GBM); Phase 2 clinical trials for the treatment of pancreatic cancer; Phase 2/3 clinical trials for the treatment of metastatic brain cancer; and Phase 2 trial for the treatment of stroke. The company is also developing RES-529, a novel PI3K/Akt/mTOR pathway inhibitor, which has completed two Phase I clinical trials for the treatment of age-related macular degeneration; and is in pre-clinical development stage for the treatment of oncology primarily GBM. Diffusion Pharmaceuticals Inc. was founded in 2001 and is headquartered in Charlottesville, Virginia.
Industry, Sector and Symbol
Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
Phone434-220-0718
Debt
Price-To-Earnings
Sales & Book Value
Annual SalesN/A
Profitability
Miscellaneous
Employees11
OptionableNot Optionable
Diffusion Pharmaceuticals (NASDAQ:DFFN) Frequently Asked Questions
What is Diffusion Pharmaceuticals' stock symbol?
Diffusion Pharmaceuticals trades on the NASDAQ under the ticker symbol "DFFN."
When did Diffusion Pharmaceuticals' stock split? How did Diffusion Pharmaceuticals' stock split work?
Diffusion Pharmaceuticals's stock reverse split on Friday, December 14th 2018. The 1-15 reverse split was announced on Thursday, December 13th 2018. The number of shares owned by shareholders was adjusted after the closing bell on Thursday, December 13th 2018. An investor that had 100 shares of Diffusion Pharmaceuticals stock prior to the reverse split would have 7 shares after the split.
How were Diffusion Pharmaceuticals' earnings last quarter?
Diffusion Pharmaceuticals Inc (NASDAQ:DFFN) issued its earnings results on Wednesday, November, 14th. The company reported ($1.95) EPS for the quarter, missing the Zacks' consensus estimate of ($0.90) by $1.05. View Diffusion Pharmaceuticals' Earnings History.
When is Diffusion Pharmaceuticals' next earnings date?
What price target have analysts set for DFFN?
1 brokerages have issued 12-month price targets for Diffusion Pharmaceuticals' shares. Their predictions range from $15.00 to $15.00. On average, they anticipate Diffusion Pharmaceuticals' share price to reach $15.00 in the next year. This suggests a possible upside of 509.8% from the stock's current price. View Analyst Price Targets for Diffusion Pharmaceuticals.
What is the consensus analysts' recommendation for Diffusion Pharmaceuticals?
1 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Diffusion Pharmaceuticals in the last year. There are currently 1 buy rating for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Diffusion Pharmaceuticals.
Has Diffusion Pharmaceuticals been receiving favorable news coverage?
News articles about DFFN stock have trended positive recently, according to InfoTrie. InfoTrie identifies positive and negative news coverage by analyzing more than six thousand news and blog sources in real time. The firm ranks coverage of companies on a scale of negative five to five, with scores closest to five being the most favorable. Diffusion Pharmaceuticals earned a news sentiment score of 2.3 on InfoTrie's scale. They also gave headlines about the company a news buzz of 6.0 out of 10, meaning that recent news coverage is somewhat likely to have an impact on the company's share price in the near future.
Who are some of Diffusion Pharmaceuticals' key competitors?
Some companies that are related to Diffusion Pharmaceuticals include Sophiris Bio (SPHS), Novan (NOVN), AzurRx BioPharma (AZRX), Catabasis Pharmaceuticals (CATB), Adial Pharmaceuticals (ADIL), Q BioMed (QBIO), Aileron Therapeutics (ALRN), IMMURON LTD/S (IMRN), Akari Therapeutics (AKTX), Advaxis (ADXS), Zosano Pharma (ZSAN), Ceapro (CRPOF), Novelion Therapeutics (NVLN), Leap Therapeutics (LPTX) and GT Biopharma (GTBP).
Who are Diffusion Pharmaceuticals' key executives?
Diffusion Pharmaceuticals' management team includes the folowing people:
- Mr. David G. Kalergis, Co-Founder, CEO & Chairman (Age 70)
- Dr. John L. Gainer, Co-Founder, Chief Scientific Officer & Director (Age 80)
- Mr. William Karl Hornung, Chief Financial Officer (Age 50)
- Mr. Thomas E. Byrne, Gen. Counsel (Age 62)
- Ms. Kelly Hoy, Director of Project Management
Who are Diffusion Pharmaceuticals' major shareholders?
Diffusion Pharmaceuticals' stock is owned by a variety of of retail and institutional investors. Top institutional shareholders include Two Sigma Investments LP (0.95%) and Virtu Financial LLC (0.54%).
Which major investors are selling Diffusion Pharmaceuticals stock?
DFFN stock was sold by a variety of institutional investors in the last quarter, including Virtu Financial LLC.
Which major investors are buying Diffusion Pharmaceuticals stock?
DFFN stock was purchased by a variety of institutional investors in the last quarter, including Two Sigma Investments LP.
How do I buy shares of Diffusion Pharmaceuticals?
Shares of DFFN can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is Diffusion Pharmaceuticals' stock price today?
One share of DFFN stock can currently be purchased for approximately $2.46.
How big of a company is Diffusion Pharmaceuticals?
Diffusion Pharmaceuticals has a market capitalization of $8.31 million. The company earns $-1,360,000.00 in net income (profit) each year or ($17.09) on an earnings per share basis. Diffusion Pharmaceuticals employs 11 workers across the globe.
What is Diffusion Pharmaceuticals' official website?
How can I contact Diffusion Pharmaceuticals?
Diffusion Pharmaceuticals' mailing address is 1317 CARLTON AVENUE SUITE 200, CHARLOTTESVILLE VA, 22902. The company can be reached via phone at 434-220-0718 or via email at [email protected]
MarketBeat Community Rating for Diffusion Pharmaceuticals (NASDAQ DFFN)
MarketBeat's community ratings are surveys of what our community members think about Diffusion Pharmaceuticals and other stocks. Vote "Outperform" if you believe DFFN will outperform the S&P 500 over the long term. Vote "Underperform" if you believe DFFN will underperform the S&P 500 over the long term. You may vote once every thirty days.
